compound introduction
SBI-477 是一种 insulin signaling 的抑制剂，可使转录因子 MondoA 失活，从而导致胰岛素途径抑制剂 thioredoxin-interacting protein (TXNIP) 和 arrestin domain-containing 4 (ARRDC4) 的表达降低。SBI-477 抑制人骨骼肌细胞中 triacylglyceride (TAG) 的合成并增强基础葡萄糖的摄取。 靶点 MondoA ; TXNIP ; ARRDC4 ; TAG Information SBI-477 SBI-477 is an insulin signaling inhibitor that deactivates the transcription factor MondoA , leading to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4) . SBI-477 inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes. Targets MondoA ; TXNIP ; ARRDC4 ; TAG
